Programme

View the 2019 Scientific Programme

 
    07:00 - 20:00 
    REGISTRATION
    08:00 - 10:00 
    ESPE Obesity Working Group (OWG)
    E2
    Tetyana Chaychenko (Kharkiv, Ukraine)
    08:00
    E2
    Session starts at 08:00
    WG2.1
    Pathogenesis of Insulin Resistance
    Ram Weiss (Jerusalem, Israel)

    08:24
    E2
    Session starts at 08:00
    WG2.2
    EU vs. non-EU practices on Insulin Resistance assessment (ESPE ObWG project)
    Tetyana Chaychenko (Kharkiv, Ukraine)

    08:48
    E2
    Session starts at 08:00
    WG2.3
    Insulin function in obese children within the low and high ranges of impaired fasting glycemia
    Claude Marcus (Solna, Sweden)

    09:12
    E2
    Session starts at 08:00
    WG2.4
    Adolescent type 2 diabetes: Comparing prospective registries
    Reinhard Holl (Ulm, Germany)

    09:36
    E2
    Session starts at 08:00
    WG2.5
    Youth onset T2D (2018 ISPAD Consensus Guidelines)
    Thomas Reinehr (Datteln, Germany)

    08:00 - 10:00 
    ESPE Working Group on Disorders of Sex Development (DSD)
    E1
    Christa Flück (Bern, Switzerland)
    08:00
    E1
    Session starts at 08:00
    Introduction
    Christa Flück (Bern, Switzerland)

    08:05
    E1
    Session starts at 08:00
    WG1.1
    Epigenetics and the androgen insensitivity syndrome
    Nadine Hornig (Kiel, Germany)

    08:25
    E1
    Session starts at 08:00
    WG1.2
    Oligogenic origin of DSD
    Nuria Camats (Barcelona, Spain)

    08:45
    E1
    Session starts at 08:00
    WG1.3
    Postpubertal outcome of boys born with hypospadias
    Lloyd Tack (Ghent, Belgium)

    09:05
    E1
    Session starts at 08:00
    WG1.4
    Shared or Shaped Decision-Making in DSD

    09:25
    E1
    Session starts at 08:00
    WG1.5
    i-dsd/i-cah
    Jillian Bryce & Faisal Ahmed (Glasgow, United Kingdom & Glasgow, United Kingdom)

    09:35
    E1
    Session starts at 08:00
    WG1.6
    Endo-ERN
    Anna Nordenström & Olaf Hiort (Stockholm, Sweden & Lübeck, Germany)

    09:45
    E1
    Session starts at 08:00
    Discussion with attendees

    09:55
    E1
    Session starts at 08:00
    Conclusion
    Tülay Güran (Turkey, Istanbul)

    08:00 - 10:00 
    ESPE Bone and Growth Plate Working Group (BGP)
    F1
    Ciara McDonnell (Dublin, Ireland)
    08:00
    F1
    Session starts at 08:00
    WG3.1
    Case presentation

    08:15
    F1
    Session starts at 08:00
    WG3.2
    Case presentation

    08:30
    F1
    Session starts at 08:00
    WG3.3
    Mechanisms of vascular calcification and potential treatment implications
    Frank Rutsch (Münster, Germany)

    09:05
    F1
    Session starts at 08:00
    WG3.4
    Update on Endo-ERN
    Agnes Linglart (France)

    09:15
    F1
    Session starts at 08:00
    WG3.5
    Update on BOND

    09:25
    F1
    Session starts at 08:00
    WG3.6
    New insights in growth plate fusion
    Katherine Staines (Edinburgh, Scotland)

    08:00 - 10:00 
    ESPE Working Group on Working Group on Diabetes Technology (DT)
    F2
    Moshe Philip (Petah Tikva, Israel)

    F2
    Session starts at 08:00
    Introduction
    Moshe Phillip (Petah Tikva, Israel)

    08:05
    F2
    Session starts at 08:00
    WG4.1
    Impact of hypoglycemia on cognitive function

    08:25
    F2
    Session starts at 08:00
    WG4.2
    Impact of hyperglycemia on cognitive function
    Jasna Šuput Omladič (Ljubljana, Slovenia)

    08:45
    F2
    Session starts at 08:00
    WG4.3
    Type 2 diabetes and the brain
    Urakami Tatsuhiko (Tokyo, Japan)

    09:05
    F2
    Session starts at 08:00
    WG4.4
    Fear of hyperglycemia
    Michal Nevo (Petah Tikva, Israel)

    09:20
    F2
    Session starts at 08:00
    WG4.5
    Time in Range (TIR) - Highlights from the consensus meeting February 2019
    Tadej Battelino (Ljubljana, Slovenia)

    09:40
    F2
    Session starts at 08:00
    WG4.6
    How technology helps to improve TIR (open and closed loop)
    Boris Kovatchev (Virginia, USA)

    08:00 - 10:00 
    ESPE Working Group on Paediatric and Adolescent Gynaecology (PAG)
    HALL B
    Anne-Simone Parent (Liège, Belgium) & Ken Ong (Cambridge, United Kingdom)
    08:00
    HALL B
    Session starts at 08:00
    WG5.1
    Early Origins of PCOS 
    Francis de Zegher (Leuven, Belgium)

    08:23
    HALL B
    Session starts at 08:00
    WG5.2
    Diagnosis & pharmacological intervention in PCOS
    Lourdes Ibáñez (Barcelona, Spain)

    08:46
    HALL B
    Session starts at 08:00
    WG5.3
    Lifestyle intervention in PCOS
    Thomas Reinehr (Dattlen, Germany)

    09:09
    HALL B
    Session starts at 08:00
    WG5.4
    Androgen Excess in female athletes 
    Angelica Lindén Hirschberg (Stockholm, Sweden)

    09:32
    HALL B
    Session starts at 08:00
    WG5.5
    Contraception in adolescence
    Kathy Hoeger (Rochester, USA)

    08:00 - 10:00 
    ESPE Working Group on Gender Dysphoria (GD)
    HALL C
    Gary Butler (London, United Kingdom)
    08:00
    HALL C
    Session starts at 08:00
    WG6.1
    Assessing competence to consent to physical treatment in transgender adolescents
    Annelou De Vries (Amsterdam, The Netherlands)

    08:30
    HALL C
    Session starts at 08:00
    WG6.2
    Surgical options for the transfemale
    Mark-Bram Bouman (Amsterdam, The Netherlands)

    09:00
    HALL C
    Session starts at 08:00
    WG6.3
    Surgical options for the transmale
    Nim Christopher (London, United Kingdom)

    09:30
    HALL C
    Session starts at 08:00
    WG6.4
    Annual General Meeting

    08:00 - 10:00 
    ESPE Working Group on Turner Syndrome (TS)
    HALL A
    Michael Ranke (Tuebingen, Germany), Aneta Gawlik (Katowice, Poland), Malcolm Donaldson (Glasgow, United Kingdom) & Christina Kanaka-Gantenbein (Athens, Greece)
    08:00
    HALL A
    Session starts at 08:00
    Introduction

    08:05
    HALL A
    Session starts at 08:00
    WG7.1
    Puberty induction - oral
    Birgit Kriström (Umeå, Sweden)

    08:20
    HALL A
    Session starts at 08:00
    WG7.2
    Puberty induction - transdermal
    Carina Ankarberg-Lindgren (Gothenburg, Sweden)

    08:40
    HALL A
    Session starts at 08:00
    WG7.3
    Endocrine management of Turner Sydndrome in adolescents and early adulthood
    Melanie Davis (London, United Kingdom)

    09:05
    HALL A
    Session starts at 08:00
    WG7.4
    Fertility preservation- technical and ethical aspects
    Kathrin Fleischer (Nijmegen, The Netherlands)

    09:30
    HALL A
    Session starts at 08:00
    WG7.5
    Cardiac morbidity and mortality during pregnancy in TS
    Anthonie Duijnhouwers (Nijmegen, The Netherlands)

    09:55
    HALL A
    Session starts at 08:00
    Closing remarks

    10:00 - 10:30 
    REFRESHMENT BREAK, POSTERS & EXHIBTION
    Exhibition Area
    10:30 - 10:45 
    OPENING CEREMONY
    HALL A
    10:45 - 11:15 
    PLENARY 1 - RANKL and RANK: Bone and beyond
    HALL A
    Gabriele Häusler (Viennna, Austria) & Agnès Linglart (Paris, France)

    HALL A
    Session starts at 10:45
    PL1
    RANKL and RANK: Bone and beyond
    Josef Penninger (Vancouver, Canada)

    11:15 - 11:45 
    ESPE AWARDS
    HALL A
    12:00 - 13:30 
    SYMPOSIUM 1
    Novel advances in Diabetes and Obesity
    HALL B
    Martin Wabitsch (Ulm, Germany) & Jan Lebl (Prague, Czech Republic)

    HALL B
    Session starts at 12:00
    S1.1
    Off the weight curve – dynamics of childhood obesity
    Antje Körner (Leipzig, Germany)


    HALL B
    Session starts at 12:00
    S1.2
    The gut microbiome and Obesity
    Frank Scott (Denver, USA)


    HALL B
    Session starts at 12:00
    S1.3
    New developments for treatments in monogenic disorders focusing on setmelanotide trials
    Christine Poitou (Paris, France)

    12:00 - 13:30 
    SYMPOSIUM 2
    What’s new in bone and growth plate research.
    E1
    Wolfgang Högler (Linz, Austria) & Dov Tiosano (Haifa, Israel)

    E1
    Session starts at 12:00
    S2.1
    Longitudinal bone growth: fundamental mechanisms to clinical applications
    Jeffrey Baron (Bethesda, USA)


    E1
    Session starts at 12:00
    S2.2
    Anabolic therapies for osteoporosis in childhood
    Frank Rauch (Montreal, Canada)


    E1
    Session starts at 12:00
    S2.3
    Steroid-Associated Osteoporosis in the Pediatric Population
    Leanne Ward (Ottawa, Canada)

    12:00 - 13:30 
    SYMPOSIUM 3
    Novel insights in our understanding of Disorders of Sex Development: From Genes to Clinical Outcomes
    HALL A
    Olaf Hiort (Lubeck, Germany) & Laura Audi (Barcelona, Spain)

    HALL A
    Session starts at 12:00
    S3.1
    Genetics of DSD – do we understand it?
    Anu Bashamboo (Paris, France)


    HALL A
    Session starts at 12:00
    S3.2
    Outcomes in DSD – insight from the DSD life study
    Anna Nordenström (Stockholm, Sweden)


    HALL A
    Session starts at 12:00
    S3.3
    Novel insights into sex determination
    Andy Greenfield (Oxford, United Kingdom)

    12:00 - 13:30 
    SYMPOSIUM 4
    ISPAD/Complications of Type 1 Diabetes
    HALL C
    Zdeněk Šumník (Prague, Czech Republic) & Thomas Danne (Hanover, Germany)

    HALL C
    Session starts at 12:00
    S4.1
    Hypoglycemia in children with T1D: Past, Present, and Future
    David Maahs (Stanford, USA)


    HALL C
    Session starts at 12:00
    S4.2
    Novel advances in diabetic retinopathy screening and management
    Kim Donaghue (Sydney, Australia)


    HALL C
    Session starts at 12:00
    S4.3
    Prediction of renal and cardiovascular complications
    Loredana Marcovecchio (Cambridge, United Kingdom)

    12:00 - 13:30 
    ESPE ACTIVITIES
    E2

    E2
    Session starts at 12:00
    ACT1.1
    Online learning project for Resource Limited Countries (RLC) Introduction
    Annemieke Boot (Groningen, The Netherlands)


    E2
    Session starts at 12:00
    ACT1.2
    Ahmad a 13 mnth old boy with failure to thrive
    Mona Karem (Ismaïlia, Egypt)

    13:30 - 14:45 
    LUNCH, POSTERS & EXHIBITION
    Exhibition Area
    13:45 - 14:45 
    Industry-Sponsored Satellite Symposia
    14:45 - 16:15 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 1 - Diabetes and Insulin Session 1
    E1
    Reinhard Holl (Ulm, Germany)
    14:45
    E1
    Session starts at 14:45
    RFC1.1
    Low prevalence of maternal microchimerism in Japanese children with type 1 diabetes
    Kikumi Ushijima (Tokyo, Japan)

    14:50
    E1
    Session starts at 14:45
    RFC1.2
    Gabra5 contributes to sexual dimorphism in POMC neural activity and glucose metabolism
    Zhou Pei (Shanghai, China)

    14:55
    E1
    Session starts at 14:45
    RFC1.3
    The association between IGF-1 levels and nonalcoholic fatty liver disease (NAFLD) in adolescents with type 2 diabetes
    Jose Antonio Orozco Morales (Mexico City, Mexico)

    15:00
    E1
    Session starts at 14:45
    RFC1.4
    Estimation of MODY frequency and prevalent subtypes in pediatric patients by targeted NGS
    Luis Salamanca (Madrid, Spain)

    15:05
    E1
    Session starts at 14:45
    RFC1.5
    Decreased circulating levels of MOTS-c in individuals with newly diagnosed type 1 diabetes children
    Caiqi Du (Wuhan, China)

    15:10
    E1
    Session starts at 14:45
    RFC1.6
    An oral trace element supplementation has a potential beneficial effect on glucose homeostasis in transfused patients with β-thalassemia major complicated with diabetes mellitus
    Nancy Elbarbary (Cairo, Egypt)

    15:15
    E1
    Session starts at 14:45
    FC1.1
    Insulin resistance leads to mitochondrial dysfunction in hepatocyte
    Hong Chen (Hangzhou, China)

    15:25
    E1
    Session starts at 14:45
    FC1.2
    Three new genes (PTPRD, SYT9, and WSF1) related to Korean maturity-onset diabetes in the young (MODY) children decrease insulin synthesis and secretion in human pancreatic beta cells
    Kyung-Mi Jang (Daegu, Republic of Korea)

    15:35
    E1
    Session starts at 14:45
    FC1.3
    Next generation sequencing in Greek MODY patients increases diagnostic accuracy and reveals a high percentage of MODY12 cases
    Amalia Sertedaki (Athens, Greece)

    15:45
    E1
    Session starts at 14:45
    FC1.4
    ABSTRACT WITHDRAWN

    15:55
    E1
    Session starts at 14:45
    FC1.5
    FADES: A birth cohort to understand the mechanisms underlying accelerated onset of autoimmunity in children with Down’s syndrome
    Georgina Williams (Chippenham, United Kingdom)

    16:05
    E1
    Session starts at 14:45
    FC1.6
    A novel biochemical marker, fatty acid-binding protein 4, in diabetic ketoacidosis in children
    Noah Gruber (Ramat Gan, Israel)

    14:45 - 15:45 
    MEET THE EXPERT 1.1
    Holistic approach to the individual with DSD
    HALL B

    HALL B
    Session starts at 14:45
    MTE1.1
    Holistic approach to the individual with DSD
    Martine Cools (Gent, Belgium)

    14:45 - 15:45 
    MEET THE EXPERT 2.1
    The interpretation of abnormal thyroid function tests in children and adolescents
    HALL C

    HALL C
    Session starts at 14:45
    MTE2.1
    The interpretation of abnormal thyroid function tests in children and adolescents
    Carla Moran (Cambridge, United Kingdom)

    14:45 - 16:15 
    HOW DO I...
    HOW DO I... SESSION 1
    HALL A
    John Gregory (Cardiff, United Kingdom)
    14:45
    HALL A
    Session starts at 14:45
    HDI1.1
    How Do I... Manage subclinical hypothyroidism
    Mariacarolina Salerno (Naples, Italy)

    15:15
    HALL A
    Session starts at 14:45
    HDI1.2
    How Do I... Manage a patient with Prader Willi and GH at transition - do they benefit as adults?
    Maithé Tauber (Toulouse, France)

    15:45
    HALL A
    Session starts at 14:45
    HDI1.3
    How do I... Manage a child with insulin resistance
    Francesco Chiarelli (Chieti, Italy)

    14:45 - 16:15 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 2 - Bone, growth plate and mineral metabolism Session 1
    E2
    Elisabeth Steichen-Gersdorf (Innsbruck, Austria) & Dirk Schnabel (Berlin, Germany)
    14:45
    E2
    Session starts at 14:45
    RFC2.1
    Burosumab resulted in better clinical outcomes than continuation with conventional therapy in both younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia
    Wolfgang Högler (Linz, Austria)

    14:50
    E2
    Session starts at 14:45
    RFC2.2
    Does the treatment with recombinant human growth hormone improve final height in patients affected by X-linked hypophosphatemia?
    Julia André (Le Kremlin Bicêtre, France)

    14:55
    E2
    Session starts at 14:45
    RFC2.3
    Growth hormone effects on metacarpal bone geometry and bone age in growth hormone-deficient children
    David D Martin (Tübingen, Germany)

    15:00
    E2
    Session starts at 14:45
    RFC2.4
    Bone mass and fracture prevalence in childhood brain cancer survivors 2, 5 or 7 years after off therapy
    Annalisa Gallizia (Genova, Italy)

    15:05
    E2
    Session starts at 14:45
    RFC2.5
    Long term effects of treatment with oxandrolone (Ox) in addition to growth hormone (GH) in girls with Turner syndrome (TS) on bone mineral density in adulthood
    Theo Sas (Rotterdam, The Netherlands)

    15:10
    E2
    Session starts at 14:45
    RFC2.6
    Impact of pubertal suppression on body composition and bone mineral density in adolescents with gender dysphoria
    Andreas Kyriakou (Glasgow, United Kingdom)

    15:15
    E2
    Session starts at 14:45
    FC2.1
    Continued improvement in clinical outcomes with burosumab, a fully human anti-FGF23 monoclonal antibody: results from a 3-year, phase 2, clinical trial in children with X-linked hypophosphatemia (XLH)
    Agnès Linglart (Le Kremlin-Bicêtre, France)

    15:25
    E2
    Session starts at 14:45
    FC2.2
    Benefits of long-term burosumab persist in 11 girls with X-linked hypophosphatemia (XLH) who transitioned into adolescence during the phase 2 CL201 trial
    Annemieke Boot (Groningen, The Netherlands)

    15:35
    E2
    Session starts at 14:45
    FC2.3
    Higher dose of burosumab is needed for treatment of children with severe forms of X linked hypophosphatemia
    Volha Zhukouskaya (Le Kremlin-Bicêtre, France)

    15:45
    E2
    Session starts at 14:45
    FC2.4
    New imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH)
    Adalbert Raimann (Vienna, Austria)

    15:55
    E2
    Session starts at 14:45
    FC2.5
    Age and gender-specific reference data for high-resolution magnetic resonance based musculoskeletal parameters in healthy children and young people
    Huda M Elsharkasi (Glasgow, United Kingdom)

    16:05
    E2
    Session starts at 14:45
    FC2.6
    Validation of a new version of BoneXpert bone age in children with congenital adrenal hyperplasia (CAH), precocious puberty (PP), growth hormone deficiency (GHD), Turner syndrome (TS), and other short stature diagnoses
    David D Martin (Tübingen, Germany)

    14:45 - 16:15 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 3 - Multi-system endocrine disorders
    F1
    Leena Patel (Manchester, United Kingdom) & Peter Bang (Linköping, Sweden)
    14:45
    F1
    Session starts at 14:45
    RFC3.1
    European Registries For Rare Endocrine Conditions (EuRRECa): results from the pilot phase of The Platform For e-Reporting Of Rare Endocrine Conditions (e-REC)
    Salma Ali (Glasgow, United Kingdom)

    14:50
    F1
    Session starts at 14:45
    RFC3.2
    Factors affecting loss to follow-up for patients with chronic endocrine conditions during the pediatric period: a cohort study at a reference center for rare diseases
    Laura Atger-Lallier (Paris, France)

    14:55
    F1
    Session starts at 14:45
    RFC3.3
    The founder homozygous NR5A1 gene mutation p.R103Q causes asplenia and severe XY-DSD and XX-DSD in a Palestinian cohort
    Maha Abdulhadi-Atwan (Hebron, Palestine)

    15:00
    F1
    Session starts at 14:45
    RFC3.4
    Peripheral glucocorticoid metabolism may reflect resolution of inflammation in Kawasaki disease
    Shuji Sai (Sapporo, Japan)

    15:05
    F1
    Session starts at 14:45
    RFC3.5
    Evaluation of endothelial function in childhood standard risk acute lymphoblastic leukemia survivors: role of subclinical markers and identification of preventable factors
    Patrizia Bruzzi (Modena, Italy)

    15:10
    F1
    Session starts at 14:45
    RFC3.6
    Prevalence of endocrine complications in Duchenne muscular dystrophy
    Primož Kotnik (Ljubljana, Slovenia)

    15:15
    F1
    Session starts at 14:45
    FC3.1
    Germline-derived gain-of-function variants of Gsα-coding GNAS gene identified in nephrogenic syndrome of inappropriate antidiuresis: the first report
    Maki Fukami (Tokyo, Japan)

    15:25
    F1
    Session starts at 14:45
    FC3.2
    CFTR loss-of-function has effects on microRNAs (miRNAs) that regulate genes involved in growth, glucose metabolism and in fertility in in vitro models of cystic fibrosis
    Francesca Cirillo (Reggio Emilia, Italy)

    15:35
    F1
    Session starts at 14:45
    FC3.3
    Variability in drug metabolizing cytochrome P450 activities caused by human genetic variations in NADPH cytochrome P450 oxidoreductase (POR)
    Maria Natalia Rojas Velazquez (Bern, Switzerland)

    15:45
    F1
    Session starts at 14:45
    FC3.4
    Droplet digital PCR is a useful method for detection of mosaic mutations in patients with McCune–Albright syndrome
    Satoshi Watanabe (Nagasaki, Japan)

    15:55
    F1
    Session starts at 14:45
    FC3.5
    Evaluation of endocrine late effects in survivors of childhood allogeneic hematopoietic stem cell transplantation in Australia database from 1985 to 2011
    Samantha Lai-Ka Lee (Melbourne, Australia)

    16:05
    F1
    Session starts at 14:45
    FC3.6
    Severe infections contribute to increased risk of early death in patients with apeced
    Joonatan Borchers (Helsinki, Finland)

    16:15 - 16:30 
    REFRESHMENT BREAK, POSTERS AND EXHIBITION
    Exhibition Area
    16:30 - 17:00 
    PLENARY 2
    Light, Body Clocks and Sleep: Biology to New Therapeutics
    HALL A

    HALL A
    Session starts at 16:30
    PL2
    Light, Body Clocks and Sleep: Biology to New Therapeutics
    Russell Foster (Oxford, United Kingdom)

    17:00 - 18:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 4 - Fat, metabolism and obesity
    E1
    Julie Chowen (Madrid, Spain) & Moshe Philip (Petah Tikva, Israel)
    17:00
    E1
    Session starts at 17:00
    RFC4.1
    Expression of miRNAs in circulating exosomes derived from patients with NAFLD
    Junfen Fu (Zhejiang, China)

    17:05
    E1
    Session starts at 17:00
    RFC4.2
    Circulating exosomal miRNAs in children’s nonalcoholic steatohepatitis and the correlation with serum transaminase and uric acid
    Xuelian Zhou (Hangzhou, China)

    17:10
    E1
    Session starts at 17:00
    RFC4.3
    Dysregulated gene expression profile in visceral adipose tissue of juvenile Wistar rats with catch-up growth: association with fat expansion and metabolic parameters
    Judit Bassols (Salt, Spain)

    17:15
    E1
    Session starts at 17:00
    RFC4.4
    The novel phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib effectively inhibits growth of PTEN haploinsufficient lipoma cells
    Anna Kirstein (Leipzig, Germany)

    17:20
    E1
    Session starts at 17:00
    RFC4.5
    GDF5 increased white adipose tissue thermogenesis through p38 MAPK signaling pathway in fatty acid-binding protein 4-GDF5 transgenic mice
    Feihong Luo (Shanghai, China)

    17:25
    E1
    Session starts at 17:00
    RFC4.6
    Appetite suppressing effects of glucoregulatory peptides devoid of nausea
    Christian L Roth (Seattle, USA)

    17:30
    E1
    Session starts at 17:00
    FC4.1
    Involvement of visfatin in adipose tissue fibrosis through modulation of extracellular matrix proteins
    Mitra Nourbakhsh (Tehran, Islamic Republic of Iran)

    17:40
    E1
    Session starts at 17:00
    FC4.2
    Characterization of the adipose progenitor cell marker MSCA1 in normal weight and obese children
    Martha Hanschkow (Leipzig, Germany)

    17:50
    E1
    Session starts at 17:00
    FC4.3
    Circulating growth-and-differentiation factor-15 in early life: relation to prenatal and postnatal size
    Marta Díaz (Barcelona, Spain)

    18:00
    E1
    Session starts at 17:00
    FC4.4
    The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 gene reduces liver damage in obese children
    Anna Di Sessa (Naples, Italy)

    18:10
    E1
    Session starts at 17:00
    FC4.5
    Leptin gene methylation status in Egyptian infants
    Omneya Magdy Omar (Alexandria, Egypt)

    18:30
    E1
    Session starts at 17:00
    FC4.6
    Brain satiety responses to a meal in children before and after weight management intervention
    Christian L Roth (Seattle, USA)

    17:00 - 18:00 
    MEET THE EXPERT 3.1
    Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
    HALL B

    HALL B
    Session starts at 17:00
    MTE3.1
    Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting
    Claus Højbjerg Gravholt (Aarhus, Denmark)

    17:00 - 18:00 
    MEET THE EXPERT 4.1
    Klinefelter syndrome - when should testosterone be started
    HALL C

    HALL C
    Session starts at 17:00
    MTE4.1
    Klinefelter syndrome - when should testosterone be started
    Julia Rohayem (Münster, Germany)

    17:00 - 18:00 
    YEARBOOK OF PAEDIATRIC ENDOCRINOLOGY 1
    HALL A
    17:00
    HALL A
    Session starts at 17:00

    17:12
    HALL A
    Session starts at 17:00
    Antenatal and Neonatal Endocrinology

    17:24
    HALL A
    Session starts at 17:00
    Bone, Growth Plate and Mineral Metabolism

    17:36
    HALL A
    Session starts at 17:00
    Global Health for the Paediatric Endocrinologist

    17:48
    HALL A
    Session starts at 17:00
    Type 2 Diabetes, Metabolic Syndrome and Lipids

    17:00 - 18:30 
    FREE COMMUNICATIONS & RAPID FREE COMMUNICATIONS 5 - Thyroid
    E2
    Malgorzata Wasniewska (Messina, Italy) & A. S. Paul Van-Trotsenburg (Amsterdam, The Netherlands)
    17:00
    E2
    Session starts at 17:00
    RFC5.1
    Hurthle cell carcinoma in childhood retrospective analysis of a large series
    Giorgia Pepe (Messina, Italy)

    17:05
    E2
    Session starts at 17:00
    RFC5.2
    Ultrasound features of multinodular goiter in DICER1 syndrome
    Marek Niedziela (Poznan, Poland)

    17:10
    E2
    Session starts at 17:00
    RFC5.3
    Experience of thyroid surgery in children with intraoperative neuromonitoring
    Alexander Anikiev (Moscow, Russian Federation)

    17:15
    E2
    Session starts at 17:00
    RFC5.4
    Thyroid dysfunction in patients following thymus transplantation in a tertiary centre: a 10-year experience
    Sommayya Aftab (London, United Kingdom)

    17:20
    E2
    Session starts at 17:00
    RFC5.5
    A novel mutation in the thyroglobulin gene leading to neonatal goiter and congenital hypothyroidism in an Eritrean infant
    Eve Stern (Ramat Gan, Israel)

    17:25
    E2
    Session starts at 17:00
    RFC5.6
    Complex single nucleotide polymorphisms in SEPINA 7 lead to TBG deficiency
    Fang Yanlan (Hangzhou, China)

    17:30
    E2
    Session starts at 17:00
    FC5.1
    Randomised trial of block and replace versus dose titration antithyroid drug treatment in children and adolescents with thyrotoxicosis
    Claire Wood (Newcastle upon Tyne, United Kingdom)

    17:40
    E2
    Session starts at 17:00
    FC5.2
    Lower proportion of CD19+IL-10+ and CD19+CD24hiCD27+ IL-10+, but not CD1d+CD5+CD19+CD24+CD27+ IL-10+ B cells in children with autoimmune thyroid diseases
    Karolina Stożek (Bialystok, Poland)

    17:50
    E2
    Session starts at 17:00
    FC5.3
    Predominant DICER1 mutations in pediatric follicular thyroid carcinomas
    Young Ah Lee (Seoul, Republic of Korea)

    18:00
    E2
    Session starts at 17:00
    FC5.4
    Thyroid dysgenesis: exome-wide analysis identifies rare variants in genes involved in thyroid development and cancer
    Stéphanie Larrivée-Vanier (Montreal, Canada)

    18:10
    E2
    Session starts at 17:00
    FC5.5
    Identification of TRPC4AP as a novel candidate gene causing thyroid dysgenesis
    Daniela Choukair (Heidelberg, Germany)

    18:20
    E2
    Session starts at 17:00
    FC5.6
    Homozygous loss-of-function mutation in the SLC26A7 gene coding a novel iodide transporter causes goitrous congenital hypothyroidism
    Atsushi Suzuki (Nagoya, Japan)

    18:30 - 20:00 
    Industry-Sponsored Satellite Symposia
    20:00 - 21:30 
    Informal ESPE Networking Event